Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02411916 · ClinicalTrials.gov registry record · NA
Effect of Adjunctive Misoprostol Treatment on Blood Loss at Vaginal Delivery
A NA study, sponsored by New York City Health and Hospitals Corporation.
- Completed
- Registry status
- NA
- Development phase
- 143
- Enrollment target
NCT02411916 is a NA study that has completed, run by New York City Health and Hospitals Corporation. The registered enrollment target is 143 participants.
The verdict
NCT02411916, a NA study, has completed, sponsored by New York City Health and Hospitals Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 143 participants
- Enrollment target
Study Summary
This document defines the Clinical Investigation Protocol for a study designed to determine whether blood loss after spontaneous vaginal delivery is altered by the addition of misoprostol administration to the standard use of intravenous oxytocin after delivery. The protocol is an open-label randomized prospective trial to be carried out at Queens Hospital Center. Blood loss will be measured indirectly by comparing the maternal hemoglobin and hematocrit levels on admission in labor to those obtained within 24 hours after delivery.
Interventions
- BIOLOGICAL misoprostol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2012-03-30 |
| Est. Completion | 2019-02-16 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02411916
The ClinicalTrials.gov registry entry for NCT02411916 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York City Health and Hospitals Corporation, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which misoprostol is the first listed.
NCT02411916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02411916 about?
NCT02411916 is a clinical study titled "Effect of Adjunctive Misoprostol Treatment on Blood Loss at Vaginal Delivery". This document defines the Clinical Investigation Protocol for a study designed to determine whether blood loss after spontaneous vaginal delivery is altered by the addition of misoprostol administration to the standard use of intravenous oxytocin after delivery. The protocol is an open-label randomi...
What is the current status of trial NCT02411916?
This trial is currently completed. It is a NA study. The enrollment target is 143 participants. The study started on 2012-03-30. Estimated completion is 2019-02-16.
What interventions are being tested in trial NCT02411916?
The interventions under investigation include: misoprostol (BIOLOGICAL).
Who is sponsoring clinical trial NCT02411916?
This trial is sponsored by New York City Health and Hospitals Corporation, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.